ProKidney (PROK) reports Q3 2025 results, beating EPS estimates. Key updates include strong Phase 3 trial enrollment and a confirmed FDA accelerated approval pathway for its kidney disease therapy.
San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results from its pivotal Phase 2 BESTOW clinical trial for tegoprubart. The drug, aimed at preventing organ rejection in kidney transplant
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the poor performance track record.
ProKidney Corp. (PROK) reports Q2 2025 results with unexpected revenue and a narrower loss than expected. FDA progress on rilparencel and Phase 3 trial updates highlight key milestones. Cash runway extends to mid-2027.
Get a pulse on the US markets on Wednesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday driven by positive clinical trial data for its CKD treatment.
